Physician profile
Deepti Rawal
NPI 1821239138
$18,627.71
in general payments reported to CMS, 2019-2025
54 companies · $2,895 in 2025
The $2,895 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $1,231 · 2021: $3,188 · 2022: $3,157 · 2023: $3,548 · 2024: $3,616 · 2025: $2,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,049.74 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,076.18 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $1,894.74 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,860.77 | 2019-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $1,319.98 | 2020-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $1,007.82 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $970.70 | 2020-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $929.52 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $914.86 | 2020-2025 | Korlym |
| Abbvie INC. | $876.81 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $826.87 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $760.22 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $633.57 | 2021-2025 | Afrezza |
| Abbott Laboratories | $387.23 | 2019-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $352.81 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Ibsa Pharma INC. | $331.69 | 2019-2025 | Tirosint, Licart, Tirosint |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $283.60 | 2023 | Tepezza |
| Amneal Pharmaceuticals LLC | $248.66 | 2021-2023 | Unithroid |
| Cequr Corporation | $247.93 | 2022-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $229.89 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $212.76 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $201.96 | 2021-2025 | Strensiq |
| Medtronic, INC. | $157.08 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Ascendis Pharma Endocrinology INC | $154.73 | 2024-2025 | Yorvipath |
| Insulet Corporation | $153.76 | 2019-2025 | Omnipod |
| Becton, Dickinson and Company | $122.05 | 2019-2022 | |
| Intra-Sana Laboratories | $100.40 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Embecta Corp. | $99.17 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $95.32 | 2021-2022 | |
| Medtronic Minimed, INC. | $95.19 | 2019 | |
| Halozyme INC | $94.16 | 2023 | |
| Tandem Diabetes Care, INC. | $87.82 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $86.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $77.72 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $63.74 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $63.22 | 2023-2025 | Isturisa, Signifor Lar |
| Ascensia Diabetes Care US INC. | $58.03 | 2023-2024 | |
| Amarin Pharma, INC. | $57.84 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $54.39 | 2019 | |
| Esperion Therapeutics, INC. | $50.84 | 2020-2021 | |
| Madrigal Pharmaceuticals | $44.69 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $44.51 | 2025 | Mycapssa |
| Amryt Pharma Holdings Ltd | $42.00 | 2022-2023 | Mycapssa |
| Companion Medical, INC. | $36.04 | 2020 | |
| Acerus Pharmaceuticals Corporation | $27.74 | 2021 | |
| Pfizer INC. | $26.54 | 2019-2020 | |
| Kyowa Kirin, INC. | $24.61 | 2023 | Crysvita |
| Alfasigma USA, INC. | $23.06 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $21.26 | 2019 | |
| Averitas Pharma INC. | $20.86 | 2025 | Qutenza |
| Lifescan, INC. | $16.22 | 2022 | |
| Sequel Med Tech, LLC | $15.95 | 2025 | Twiist |
| Shire North American Group INC | $15.54 | 2019 | |
| Vistapharm, INC. | $15.00 | 2021 | |
| Aytu Biopharma, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepti Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.